The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Chronic myeloid leukemia (CML) is probably the most extensively studied human
malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first …

An extraordinary series of discoveries about chronic myeloid leukemia (CML) has made this
disease a model of the way in which bench and bedside research can unite and culminate …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Development of safe and effective cancer vaccine formulation is a primary focus in the field
of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in …

There is consensus that an optimized cancer vaccine will have to induce not only CD8+
cytotoxic but also CD4+ T helper (Th) cells, particularly interferon (IFN)-γ–producing, type 1 …

Many human tumor-associated antigens (TAAs) have recently been identified and
molecularly characterized. When bound to major histocompatibility complex molecules, TAA …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …